Panel discussion on November 9 at Wonderland: Miami will review the benefits of ketamine treatment for depression and other mental…
Category: Psychedelic
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
Achieving its second FDA orphan drug designation with ketamine. Building a proprietary ketamine-based product pipeline for…
Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics,…
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage…
Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
Additional lab facility and federal licence application add expanded contract services to portfolio VANCOUVER, BC, Oct. 8,…
Red Light Holland Expands the iMicrodose Brand and Unveils New iMicrodose Products: Triniti, Uniti and Mindfuli
Toronto, Ontario–(Newsfile Corp. – October 8, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX)…
Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1
Toronto, Ontario–(Newsfile Corp. – October 7, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company”…
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
TORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF)…
MindMed Announces Strategic Research Collaboration with Sphere Health
NEW YORK, Oct. 5, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”),…
Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD
Plans to Develop and Launch A Global Registry For The Identification and Long Term Management of…
Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development
Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics,…
PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF)…